Clinical benefit with PEMAZYRE — 2 of 3

PEMAZYRE provides a new treatment option in ≥2L CCA

Clinically meaningful anti-tumour activity was observed with PEMAZYRE1,29

Best percentage change from baseline in target lesion size for individual patients with FGFR2 fusions or rearrangements29

Histogram showing best percentage change from baseline in target lesion size

Tumour response was assessed by independent review. Coloured bars indicate confirmed responses assessed by RECIST v1.1.
Dotted lines indicate the cutoff for partial response (–30%) and progressive disease (+20%).
*Patient had a decrease in target lesion size but was not evaluable for response using RECIST.
Figure reprinted from Abou-Alfa GK, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Lancet Oncol. 2020;21:671–84. Copyright © 2020 with permission from Elsevier Ltd. All rights reserved.

For further efficacy information, please refer to the PEMAZYRE Summary of Product Characteristics.1